Depression and metabolic factors together raise the risk of developing type 2 diabetes, study finds
Depression can significantly increase the likelihood of developing type 2 diabetes when it occurs alongside early metabolic warning signs such as obesity, high blood pressure and adverse cholesterol or triglyceride levels. Researchers from McGill University, Université de Montréal, the Institut de recherches cliniques de Montréal and the University of Calgary report that the combined impact of depressive symptoms and metabolic dysregulation exceeds the risk posed by each condition alone.
Published in Molecular Psychiatry, the study adds nuance to previous work linking depression and diabetes by showing a synergistic effect: depressive symptoms and metabolic risk factors interact to multiply diabetes risk rather than simply adding their individual contributions.
“Emerging evidence suggests that not depression by itself, but depression combined with behavioral and metabolic risk factors increases the risk of developing type 2 diabetes and cardiovascular disease,” said lead author Norbert Schmitz, Associate Professor in McGill’s Department of Psychiatry and researcher at the Douglas Mental Health University Institute. “Our goal was to better characterize people who have both depressive symptoms and metabolic risk factors so prevention and treatment can be targeted.”
Study design and key results
The longitudinal study followed 2,525 adults in Quebec, aged 40 to 69, over 4.5 years. Participants were assigned to four groups based on the presence or absence of depressive symptoms and a cluster of metabolic risk factors (obesity, elevated fasting glucose, high blood pressure, high triglycerides and low HDL cholesterol): (1) both depressive symptoms and metabolic dysregulation, (2) depressive symptoms only, (3) metabolic dysregulation only, and (4) neither condition (reference group).
During follow-up, 87 individuals (3.5%) were diagnosed with diabetes. The analysis showed that people with metabolic dysregulation but no depressive symptoms were about four times more likely to develop diabetes than the reference group (adjusted odds ratio ≈ 4.4). Those with depressive symptoms alone did not have a significantly higher risk than the reference group (adjusted odds ratio ≈ 1.28). Crucially, participants with both depressive symptoms and metabolic dysregulation had the highest risk—more than six times greater than the reference group (adjusted odds ratio ≈ 6.61).
Statistical measures of interaction indicated the combined effect of depressive symptoms and metabolic dysregulation exceeded the sum of their individual effects, suggesting a synergistic relationship that amplifies diabetes risk.
How the interaction may work
The researchers highlight several pathways that could explain the interaction between depression, metabolic dysregulation and diabetes risk. Behaviorally, depression often undermines adherence to healthy habits and medical recommendations—making it harder to stop smoking, maintain regular exercise, follow a balanced diet or consistently take medications designed to control blood pressure, cholesterol and glucose. Poor management of metabolic risk factors can then worsen metabolic health and increase vulnerability to type 2 diabetes.
Biologically, certain depressive states are associated with hormonal and inflammatory changes that promote weight gain, elevated blood pressure and impaired glucose metabolism. Additionally, some antidepressant medications may contribute to weight gain, which can compound metabolic risk in susceptible individuals.
Implications for prevention and treatment
The study suggests that not all patients with depression carry the same medical risk. Targeted screening to identify people who have both depressive symptoms and metabolic dysregulation could enable more effective, integrated interventions. Treating depression alone without addressing lifestyle and metabolic factors may leave patients at elevated risk for poor health outcomes and recurrent depressive episodes.
“Focusing exclusively on depression may not change lifestyle or metabolic risk factors, leaving people vulnerable to poorer health outcomes and higher chances of recurrent depression,” Prof. Schmitz explained. The authors recommend early identification, monitoring and combined management of depressive symptoms and metabolic abnormalities as a potential diabetes prevention strategy.
This project was supported by the Canadian Institutes of Health Research (CIHR) and the Fonds de recherche du Québec – Santé. The study used data from the Emotional Health and Wellbeing Study (EMHS) in Quebec, applying a two-way stratified sampling design to examine how depressive symptoms interact with metabolic dysregulation to influence diabetes risk.
Source: Katherine Gombay – McGill University
Image credit: Public domain image
Original research: Abstract for “Depression and risk of type 2 diabetes: the potential role of metabolic factors” by N. Schmitz et al., Molecular Psychiatry. Published online February 23, 2016. doi:10.1038/mp.2016.7
Abstract (summary)
This study evaluated whether depressive symptoms and metabolic dysregulation interact to increase the risk of type 2 diabetes. Among 2,525 adults followed for 4.5 years, 87 developed diabetes. The highest risk was observed in participants who had both depressive symptoms and metabolic dysregulation (adjusted odds ratio = 6.61). Depressive symptoms without metabolic problems were not significantly associated with higher diabetes risk, while metabolic dysregulation without depression increased risk substantially (adjusted odds ratio = 4.40). Statistical interaction measures suggested the combined effect of depression and metabolic dysregulation exceeded the sum of their separate effects. The findings support early identification and integrated management of these co-occurring conditions to reduce diabetes risk.